Media Contacts

For more information contact our media team:

Stacy Sevcik
+1 314 529 3062
Send Email >

Next Event

  • e-Health Research International Congress 2016

    Paris, France
    Oct11 – 12, 2016

    Learn More

Kantar Health thought leaders are available to comment on a variety of healthcare- and pharma-industry-related topics. In addition, our proprietary data is available for media use, including patient population sizes, treatment rates and patient-reported behaviors and attitudes.

Welcome to the Kantar Health News Room RSS Feed News

Delivering the most current and unique insights on healthcare trends and news about Kantar Health.

Nexavar Use in Chinese HCC Patients Nearly Doubled in 2012

Dec 19, 2012

New Research from Kantar Health Also Shows Chinese Physicians Are Adopting More Western Treatment Practices in NSCLC

NEW YORK, December 19, 2012—Use of Nexavar® (sorafenib, Onyx Pharmaceuticals/Bayer) has nearly doubled in first-line advanced hepatocellular carcinoma (HCC) patients in China in 2012 from 2011, according to new findings from CancerMPact® Treatment Architecture China, conducted by Kantar Health, a leading healthcare-focused global consultancy and marketing insights company, and Draco Healthcare, Inc., a leading China-focused consultancy.

“Nexavar quickly became the standard of care for HCC in Western markets when it was first approved five years ago; however, Chinese physicians have historically relied on 5-FU-based regimens,” said Neesha Suvarna, Ph.D., Consultant with Kantar Health. “Our most recent physician survey data shows that Nexavar adoption is increasing in China. While the utilization of Nexavar in HCC is smaller in China compared with the West, the growth trend we observe suggests that there is a high potential for growth.”

In addition, Kantar Health’s research found that use of Alimta® (pemetrexed, Lilly) is gradually increasing in non-squamous non-small cell lung cancer (NSCLC) patients in China since its approval in 2011. Also gaining in use are EGFR biomarker testing and EGFR-targeting agents, such as Tarceva® (erlotinib, Genentech/Roche/Astellas) and Iressa® (gefitinib, AstraZeneca) in Chinese patients who are EGFR-mutant.

“China has traditionally faced a drug approval and adoption lag, and our recent data suggests that Chinese physicians are slowly adopting Western treatment practices,” Dr. Suvarna said.  “There are multiple barriers to adoption, including the high price of agents and lack of reimbursement. However, support from patient access programs, increasing patient education and availability of cheaper drugs or generics might all play a role in slowly revolutionizing treatment practices in China.”

CancerMPact® Treatment Architecture China is a clinically rich multiclient offer that focuses on key tumor types in China. The subscription provides an in-depth analysis of the current clinical management of cancer by stage of disease for all treatment modalities. The latest updates to CancerMPact® Treatment Architecture China include the following tumor types:

  • Breast cancer
  • Hepatocellular carcinoma
  • Non-small cell lung cancer
  • Ovarian cancer

About Kantar Health (

Kantar Health is a global, evidence-based decision support partner to the world’s leading pharmaceutical, biotech, device and diagnostic companies. Our 700+ staff act as catalysts, working closely with customers to drive distinctive decision-making that helps them prioritize product development and portfolios, differentiate their brands and ensure product profitability after launch. We are unique in that we bring together clinical, medical and methodological expertise, commercial/marketing know-how and proprietary data. It is this rare combination, together with our unparalleled stakeholder reach, that enables us to mobilize incisive, imaginative and timely ROI-driven solutions, empowering clients to deliver better healthcare options to their customers.


With staff in over 40 countries, we excel at solving technically or logistically challenging projects around the world and across the product lifecycle, combining on-the-ground know-how and global and national proprietary data to quickly identify value drivers. As part of WPP, we can also incorporate highly innovative thinking from outside the industry into our solutions.


About Draco Healthcare (

Draco Healthcare, Inc. is a leader in healthcare consulting focusing on the greater China region, and is committed to providing consulting services of the highest quality to leading pharmaceutical and biotech companies worldwide. Draco focuses exclusively on China’s healthcare market, including pharmaceutical industry analysis, Chinese drug regulatory environment, China’s unique hospital systems, and China’s complicated epidemiology data. Draco has a dedicated professional team composed of experienced healthcare consultants from pharmaceuticals and biotech industry veterans, experts on State Food and Drug Administration (SFDA), and on China epidemiology data. Draco’s proprietary oncology databases, tools, and multi-client reports include:

  • China CancerMPact® Treatment Architecture Report (co-developed with Kantar Health)
  • China Epidemiology Report (cancers and non-cancer diseases)
  • China Hospital Prescription Drug (CPD) Sales Reports


Contact Information

For more information on Kantar Health, please contact Stacy Sevcik, Marketing Manager, at or +1-314-529-3062.